Hoxa11as long non-coding rna in inflammatory bowel disease
AssigneeUniversity of Massachusetts
InventorsKatherine A. FITZGERALD, Liraz GALIA
Life of this patent
Estimating the term…
Abstract
Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Claims16
A method of diagnosing inflammatory bowel disease (IBD) in a subject, the method comprising:
- providing a sample from the subject;
- detecting a level of a HOXA11AS in the sample;
- and
- comparing the level of the HOXA11AS in the sample to a reference level;
- wherein presence of a level of HOXA11AS below the reference level indicates that the subject has IBD.
A method comprising:
- providing a sample from a subject known or suspected to have IBD;
- and
- detecting a level of a HOXA11AS in the sample;
- and optionally
- comparing the level of the HOXA11AS in the sample to a reference level.
A method of treating IBD in a subject, the method comprising administering to the subject a HOXA11AS nucleic acid comprising the isolated nucleic acid of claim 11 to cells in the intestine of the subject, optionally to myeloid cells in the intestine of the subject.
An isolated nucleic acid encoding HOXA11AS, optionally wherein the HOXA11AS is at least 80%, 85%, 90%, 95%, or 99% identical to SEQ ID NO:5 or 6.
-20. (canceled)
Dependencies are inferred from the claim text.